biote (BTMD) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
2 Apr, 2026Voting matters and shareholder proposals
Election of two Class I directors, Andrew R. Heyer and Dana Jacoby, to serve until the 2029 annual meeting or until successors are qualified.
Ratification of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Board recommends voting for all director nominees and for the auditor ratification proposal.
Additional business may be transacted as properly brought before the meeting or any adjournments.
Board of directors and corporate governance
Board is structured with Class I directors up for election, indicating a staggered board structure.
Audit committee and external auditor matters
Deloitte & Touche LLP proposed for ratification as the independent registered public accounting firm for the 2026 fiscal year.
Latest events from biote
- Q2 2026 revenue fell 9.5% to $44.2M, with a net loss of $7.4M due to a major product recall.BTMD
Q2 2026 - Recall-driven supply issues led to lower Q1 revenue, but growth is expected to resume in H2 2026.BTMD
Q1 2026 - Board recommends electing two directors and ratifying Deloitte as auditor at the annual meeting.BTMD
Proxy filing - 2025 revenue and margins fell, but investments aim for renewed growth in H2 2026.BTMD
Q4 2025 - Q3 revenue up 12.8% to $51.4M; 2024 guidance trimmed amid software and hurricane impacts.BTMD
Q3 2024 - Q2 2024 saw procedure growth, strong margins, narrowed net loss, and reaffirmed 2024 guidance.BTMD
Q2 2024 - Strong growth, tech-driven wellness expansion, and broad U.S. market opportunity highlighted.BTMD
Jefferies 2024 Global Healthcare Conference - Q1 2025 net income reached $15.8M on 4.7% revenue growth and strong supplement sales.BTMD
Q1 2025 - Q4 revenue up 9%, margin gains, and 2025 outlook projects further growth and profitability.BTMD
Q4 2024